Bristol Myers pays $350M upfront for rights to heart drug Camzyos in Asia
Bristol Myers Squibb is setting up a deal with Shanghai-based LianBio to get the rights to the heart drug Camzyos in China and several other Asian countries after buying the drug’s developer in 2020.
The companies announced Tuesday that Bristol Myers will pay LianBio $350 million upfront in exchange for the rights to develop and commercialize Camzyos, or mavacamten, in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
